Alcalá C, et al. - Study authors attempted to examine the effectiveness and safety of rituximab in multiple sclerosis (MS). In this analysis, an aggregate of 90 rituximab-treated patients was collected: 31 relapsing-remitting (RRMS) and 59 progressive multiple sclerosis (PMS) all patients had an active disease despite standard treatment. Results revealed that the annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. No evidence of disease activity was observed in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. The findings suggested that rituximab could be an effective and safe treatment in aggressive RRMS. They observed that some selected PMS patients could also benefit from this treatment.